AstraZeneca Valuation
Is AZN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of AZN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: AZN (ARS36475) is trading below our estimate of fair value (ARS59966.98)
Significantly Below Fair Value: AZN is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for AZN?
Key metric: As AZN is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is AZN's PE Ratio? | |
|---|---|
| PE Ratio | 31.3x |
| Earnings | US$6.50b |
| Market Cap | US$203.47b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 4.5x |
| Enterprise Value/EBITDA | 12.4x |
| PEG Ratio | 1.7x |
Price to Earnings Ratio vs Peers
How does AZN's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 20.9x | ||
MRK Merck | 20.7x | 15.6% | US$250.9b |
NOVN Novartis | 17.8x | 7.0% | CHF 187.3b |
ROG Roche Holding | 19.1x | 11.1% | CHF 204.3b |
SAN Sanofi | 25.9x | 17.9% | €116.8b |
AZN AstraZeneca | 31.3x | 18.4% | AR$162.4b |
Price-To-Earnings vs Peers: AZN is expensive based on its Price-To-Earnings Ratio (31.3x) compared to the peer average (20.9x).
Price to Earnings Ratio vs Industry
How does AZN's PE Ratio compare vs other companies in the Global Pharmaceuticals Industry?
| 24 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 24 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: AZN is expensive based on its Price-To-Earnings Ratio (31.3x) compared to the Global Pharmaceuticals industry average (22.6x).
Price to Earnings Ratio vs Fair Ratio
What is AZN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 31.3x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate AZN's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Biogen
US$23.0b
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally.
BIIBD
US$13.35
7D
2.7%
1Y
n/a
GSK
UK£54.8b
Engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
GSKD
UK£8.80
7D
-17.8%
1Y
-1.1%
Novartis
CHF 187.3b
Engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally.
NVS
CHF 28,950.00
7D
-1.1%
1Y
21.1%